Caris Life Sciences (CAI) Assets Average (2025 - 2026)

Caris Life Sciences (CAI) posted quarterly Assets Average of $1.1 billion for Q1 2026, up 8.43% quarter-over-quarter from $1.1 billion in Q4 2025.

Caris Life Sciences (CAI) Assets Average (2025 - 2026) Analysis & Trends

Caris Life Sciences' Assets Average history runs 2 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

In Q1 2026, Assets Average changed N/A year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (changed N/A YoY), while the FY2025 annual figure was $734.7 million, changed N/A from the prior year.
Assets Average for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
The five-year high for Assets Average was $1.1 billion in Q1 2026, with the low at $969.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	26.95 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	41.30 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	3.29 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	8.86 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	16.08 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.82 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	5.34 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	2.09 Bn
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	1.20 Bn

Download Data